Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 4/2014

01-04-2014 | Original article

Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma

Final report of a pilot study

Authors: M. Balducci, B. Diletto, S. Chiesa, G.R. D’Agostino, M.A. Gambacorta, M. Ferro, C. Colosimo, G. Maira, C. Anile, V. Valentini

Published in: Strahlentherapie und Onkologie | Issue 4/2014

Login to get access

Abstract

Backgroud

Evaluated in this study were the feasibility and the efficacy of concurrent low dose fractionated radiotherapy (LD-FRT) and chemotherapy as palliative treatment for recurrent/progressive glioblastoma multiforme (GBM).

Patients and methods

Eligible patients had recurrent or progressive GBM, Karnofsky performance status ≥ 70, prior surgery, and standard radiochemotherapy treatment. Recurrence/progression disease during temozolomide (TMZ) received cisplatin (CDDP; 30 mg/m2 on days 1, 8, 15), fotemustine (FTM; 40 mg/m2 on days 2, 9, 16), and concurrent LD-FRT (0.3 Gy twice daily); recurrence/progression after 4 months from the end of adjuvant TMZ were treated by TMZ (150/200 mg/m2 on days 1–5) concomitant with LD-FRT (0.4 Gy twice daily). Primary endpoints were safety and toxicity.

Results

A total of 32 patients were enrolled. Hematologic toxicity G1–2 was observed in 18.7 % of patients and G3–4 in 9.4 %. One patient (3.1 %) had complete response, 3 (9.4 %) had partial response, 8 (25 %) had stable disease for at least 8 weeks, while 20 patients (62.5 %) experienced progressive disease. The clinical benefit was 37.5 %. Median progression-free survival (PFS) and overall survival (OS) were 5 and 8 months, respectively. Survival rate at 12 months was of 27.8 %.

Conclusion

LD-FRT and chemotherapy for recurrent/progressive GBM have a good toxicity profile and clinical outcomes, even though further investigation of this novel palliative treatment approach is warranted.
Literature
1.
Guckenberger M, Mayer M, Buttmann M et al (2011) Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther Onkol 187(9):548–554PubMedCrossRef
2.
Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML (1998) Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 174(12):629–632PubMedCrossRef
3.
American Cancer Society (2008) Cancer facts & figures 2008. American Cancer Society, Atlanta
4.
Stupp R, Mason WP, Bent MJ van den et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
5.
Jansen EP, Dewit LG, Herk M van, Bartelink H (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56(2):151–156PubMedCrossRef
6.
Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16(6):1405–1409PubMedCrossRef
7.
Chamberlain MC, Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 168(2):114–120PubMedCentralPubMed
8.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729PubMedCrossRef
9.
Tselis N, Kolotas C, Birn G et al (2007) CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol 183(10):563–570PubMedCrossRef
10.
Henke G, Paulsen F, Steinbach JP et al (2009) Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 185(2):113–119PubMedCrossRef
11.
Fokas E, Wacker U, Gross MW (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185(4):235–240PubMedCrossRef
12.
Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trial. J Clin Oncol 17:2572–2578PubMed
13.
Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CC1-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 23:5294–5304PubMedCrossRef
14.
Niyazi M, Siefert A, Schwarz SB et al (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98(1):1–14PubMedCrossRef
15.
Perry JR, Rizek P, Cashman R et al (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113(8):2152–2157PubMedCrossRef
16.
Short SC, Mitchell SA, Boulton P et al (1999) The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol 75:1341–1348PubMedCrossRef
17.
Short S, Mayes C, Woodcock M et al (1999) Low-dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 75:847–855PubMedCrossRef
18.
Beauchesne PD, Bertrand S, Branche R et al (2003) Human malignant glioma cell lines are sensitive to low radiation doses. Int J Cancer 105:33–40PubMedCrossRef
19.
Krause M, Wohlfarth J, Georgi B et al (2005) Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 81(10):751–758PubMedCrossRef
20.
Chendil D, Oakes R, Alcock RA et al (2000) Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer 89:1893–1900PubMedCrossRef
21.
Short SC, Kelly J, Mayes CR et al (2001) Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol 77:655–664PubMedCrossRef
22.
Dey S, Spring PM, Arnold S et al (2003) Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9:1557–1565PubMed
23.
Gupta S, Arnold AM, Spring P et al (2004) Low-dose fractionated radiation potentiates the effect of cisplatin independent of the hyper-radiation sensitivity phenomenon in human lung cancer cell lines [Abstract]. Proc Am Assoc Cancer Res 45
24.
Arnold SM, Regine WF, Ahmed MM et al (2004) Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 58:1411–1417PubMedCrossRef
25.
Spring PM, Arnold SM, Shajahan S et al (2004) Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 3:479–485PubMedCrossRef
26.
Regine WF, Hanna N, Garofalo MC et al (2007) Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 68(1):172–177PubMedCrossRef
27.
Simpson L, Galanis E (2006) Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 6(11):1593–1607PubMedCrossRef
28.
Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786PubMedCrossRef
29.
Franceschi E, Omuro AM, Lassman AB et al (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476PubMedCrossRef
30.
Meulemans A, Giroux B, Hannoun P et al (1991) Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy 37:86–92PubMedCrossRef
31.
Fischel JL, Formento P, Etienne MC, Gioanni J et al (1990) In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 25:337–341PubMedCrossRef
32.
Fabrini MG, Silvano G, Lolli I et al (2009) A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92(1):79–86PubMedCrossRef
33.
Scoccianti S, Detti B, Sardaro A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19(6):613–620PubMedCrossRef
34.
De Wit MC, Bruin HG de, Eijkenboom W et al (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537CrossRef
35.
Emami B, Lyman j, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRef
36.
37.
Balducci M, D’Agostino GR, Manfrida S et al (2010) Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neurooncol 97(1):95–100PubMedCrossRef
38.
De Bonis P, Anile C, Pompucci A et al (2012) Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 154(8):1371–1378
39.
Rodier JM, Da Costa L, Adams D et al (1996) Fotemustine and cisplatin association in patients with recurrent malignant glioma. Proc Am Sol Clin
40.
Lambin P, Malaise EP, Joiner MC (1994) The effect of very low radiation doses on the human bludder cell line RT112. Radiother Oncol 32:63–72PubMedCrossRef
41.
Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v4.0. ctep.cancer.gov/reporting/ctc.html. Accessed 29. Dec 2013
42.
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed
43.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008 (Revised March 23, 2012). http://​www.​cbtrus.​org/​reports/​reports.​html.​ Accessed 29. Dec 2013
44.
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef
45.
Taghian A, Ramsay J, Allalunis-Turner J et al (1993) Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 25(2):243–249PubMedCrossRef
46.
Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells—potential partners in glioma drug resistance? Cancer Treat Rev 34(6):558–567PubMedCrossRef
47.
Lowe SW, Ruley HE, Jacks T, Housman DE et al (1993) P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967PubMedCrossRef
48.
Benjamin B, David C, Dieter L et al (2010) Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol 12(9):894–907CrossRef
49.
Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181–193PubMedCrossRef
50.
Franceschi E, Tosoni A, Bartolini S et al (2009) Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther 9(5):613–619PubMedCrossRef
51.
Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343–359PubMedCrossRef
52.
Attenello FJ, Mukherjee D, Datoo G et al (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15(10):2887–2893PubMedCrossRef
53.
Hart MG, Grant R, Garside R et al (2008) Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294PubMed
54.
Gilbert MR (2011) Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Semin Oncol 38(Suppl 4):S21–S33PubMedCrossRef
55.
Marples B, Wouters BG, Collis SJ et al (2004) Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiationdamaged G2-phase cells. Radiat Res 161:247–255PubMedCrossRef
56.
Enns L, Bogen KT, Wizniak J et al (2004) Low- dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res 2(10):557–566PubMed
57.
Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155–1160PubMedCentralPubMedCrossRef
58.
Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266PubMedCrossRef
59.
Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with Glioblastoma multiforme at first relapse. Br J Cancer 83:588–593PubMedCentralPubMedCrossRef
60.
Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115PubMedCrossRef
61.
Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361PubMedCrossRef
62.
Joiner MC, Denekamp J, Maughan RL (1986) The use of ‘top-up’ experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol Relat Stud Phys Chem Med 49:565–580PubMedCrossRef
63.
Joiner MC, Johns H (1988) Renal damage in the mouse: the response to very small doses per fraction. Radiat Res 114:385–398PubMedCrossRef
64.
Turesson I, Nyman J, Qvarnström F et al (2010) A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis. Radiother Oncol 94(1):90–101PubMedCrossRef
65.
Rachidi W, Harfourche G, Lemaitre G et al (2007) Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol 83(3):267–276PubMedCrossRef
66.
Gay H (2010) Role of the linear-quadratic model in high doses per fraction. Radiother Oncol 94(1):122–123CrossRef
67.
Courdi A (2010) High doses per fraction and the linear-quadratic model. Radiother Oncol 94(1):121–122PubMedCrossRef
68.
Short SC, Woodcock M, Marples B, Joiner MC et al (2003) Effects of cell cycle phase on low-dose hyper-radiosensitivity. Int J Radiat Biol 79(2):99–105PubMedCrossRef
69.
Beauchesne P, Bernier V, Carnin C et al (2010) Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol 12(6):595–602PubMedCentralPubMedCrossRef
70.
Valentini V, Massaccesi M, Balducci M et al (2010) Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys 76:535–539PubMedCrossRef
71.
Mantini G, Valentini V, Meduri B et al (2102) Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study. Radiother Oncol 105:161–166CrossRef
72.
Balducci M, Chiesa S, Diletto B et al (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14:79–86PubMedCentralPubMedCrossRef
Metadata
Title
Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma
Final report of a pilot study
Authors
M. Balducci
B. Diletto
S. Chiesa
G.R. D’Agostino
M.A. Gambacorta
M. Ferro
C. Colosimo
G. Maira
C. Anile
V. Valentini
Publication date
01-04-2014
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 4/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0506-z

Other articles of this Issue 4/2014

Strahlentherapie und Onkologie 4/2014 Go to the issue

Original article

Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institution

Case study

Bevacizumab treatment in malignant meningioma with additional radiation necrosis

Case study

Temozolomide-induced liver damage

Original article

Evaluation of time, attendance of medical staff, and resources during interstitial brachytherapy for prostate cancer

Original article

Quality of patient positioning during cerebral tomotherapy irradiation using different mask systems

Literatur kommentiert

Intraoperative Teilbrustbestrahlung mit Elektronen versus konventionelle externe Ganzbrustbrustbestrahlung beim frühen Mammakarzinom